Breakthrough T1D has updated this cycle's priorities to focus on clinical trials and therapies that improve cardiovascular outcomes in people with type 1 diabetes. If you plan to apply, please note new requirements to secure your own study drug with a written manufacturer commitment and provide a feasibility plan for your clinical trial sites.
Funder: Breakthrough T1D
Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full Proposal, by invitation)
Funding Amounts: Up to $3,000,000 total over 3 years; company matching funds required; no indirect costs.
Summary: Supports for-profit companies developing therapies or devices for type 1 diabetes, with emphasis on projects advancing innovative, commercially promising solutions.
Key Information: LOI required; applicants must contact Breakthrough T1D before submitting.